Skip to main content

Table 4 Final regression models (SF 36 domains)

From: Factors associated with health-related quality of life in renal transplant recipients: results of a national survey in France

Dimensions

Variables

β coeff.

95% CI

P values

PF R2 = 0.31

Intercept

95.4

[91.1; 99.6]

p < .0001

 

Female

-4.7

[-7.6; -1.7]

p < 0.0018

 

Age ≥ 75 years

-23.3

[-30.4; -16.2]

p < .0001

 

Low educational (primary or less)

-7.5

[-11.2; -3.8]

p < .0001

 

Unemployment

-6.3

[-9.4; -3.2]

p < .0001

 

BMI > 30 (kg/m2)

-5.8

[-10; -1.6]

p < 0.0065

 

Critical illness in the last 4 weeks

-8.0

[-14.9; -1.1]

p < 0.0237

 

Diabetes

-5.6

[-10.1; -1]

p < 0.0163

 

Side effects related to general health

-17.0

[-20.9; -13.1]

p < .0001

 

Side effects related to mental health

-6.8

[-10.5; -3]

p < 0.0004

 

Recent surgery

-9.5

[-24.9; 6]

p < 0.2283

 

Infectious disease in the last 4 weeks

-4.8

[-9.1; -0.4]

p < 0.0311

RP R2 = 0.22

Intercept

90.5

[82.8; 98.1]

p < .0001

 

Female

-6.9

[-12.2; -1.6]

p < 0.0104

 

Age ≥ 75 years

-20.1

[-33.1; -7]

p < 0.0026

 

Low educational (primary or less)

-11.4

[-18; -4.8]

p < 0.0007

 

Hospitalization in the last 4 weeks

-17.9

[-27.1; -8.8]

p < 0.0001

 

Critical illness in the last 4 weeks

-31.5

[-44.8; -18.1]

p < .0001

 

Infectious disease in the last 4 weeks

-10.9

[-19; -2.9]

p < 0.0080

 

Side effects related to general health

-21.5

[-28.7; -14.3]

p < .0001

 

Side effects related to mental health

-16.0

[-22.8; -9.1]

p < .0001

BP R2 = 0.23

Intercept

85.3

[80.6; 90]

p < .0001

 

Female

-4.9

[-8.1; -1.6]

p < 0.0035

 

Age ≥ 75 years

-8.3

[-16.1; -0.4]

p < 0.0402

 

Low educational (primary or less)

-6.5

[-10.5; -2.5]

p < 0.0016

 

Infectious disease in the last 4 weeks

-9.1

[-14; -4.3]

p < 0.0002

 

Side effects related to general health

-18.7

[-23.2; -14.2]

p < .0001

 

Side effects related to mental health

-9.7

[-14; -5.4]

p < .0001

 

Side effects related to body modification

-4.2

[-7.7; -0.7]

p < 0.0193

MH R2 = 0.24

Intercept

81.1

[77.7; 84.6]

p < .0001

 

Female

-5.6

[-8; -3.3]

p < .0001

 

Family status (living alone)

-4.6

[-7.2; -1.9]

p < 0.0007

 

Duration of dialysis > 3 years

-3.3

[-5.8; -0.8]

p < 0.0087

 

Hospitalization in the last 4 weeks

-7.7

[-11.4; -4]

p < .0001

 

Side effects related to mental health

-16.5

[-19.5; -13.5]

p < .0001

 

Side effects related to body modification

-4.4

[-6.9; -1.9]

p < 0.0005

RE R2 = 0.18

Intercept

94.8

[86.5; 103]

p < .0001

 

Female

-6.4

[-12; -0.8]

p < 0.0252

 

Low educational (primary or less)

-16.8

[-24; -9.6]

p < .0001

 

Age ≥ 75 years

-11.1

[-25.3; 3.2]

p < 0.1285

 

Family status (living alone)

-9.1

[-15.3; -2.8]

p < 0.0045

 

Hospitalization in the last 4 weeks

-17.4

[-26.7; -8.1]

p < 0.0003

 

Infectious disease in the last 4 weeks

-19.1

[-27.6; -10.7]

p < .0001

 

Side effects related to mental health

-25.0

[-32; -18.1]

p < .0001

SF R2 = 0.25

Intercept

90.8

[86.8; 94.8]

p < .0001

 

Female

-4.9

[-7.6; -2.1]

p < 0.0006

 

Family status (living alone)

-4.6

[-7.8; -1.5]

p < 0.0036

 

Hospitalization in the last 4 weeks

-11.8

[-16.2; -7.3]

p < .0001

 

Infectious disease in the last 4 weeks

-7.2

[-11.5; -2.9]

p < 0.0011

 

Diabetes

-7.5

[-11.5; -3.5]

p < 0.0002

 

Side effects related to general health

-11.3

[-15; -7.6]

p < .0001

 

Side effects related to mental health

-16.4

[-20; -12.8]

p < .0001

VT R2 = 0.22

Intercept

62.8

[59.6; 66.1]

p < .0001

 

Female

-2.4

[-4.6; -0.1]

p < 0.0366

 

Hospitalization in the last 4 weeks

-8.3

[-11.8; -4.8]

p < .0001

 

Side effects related to general health

-12

[-15; -8.9]

p < .0001

 

Side effects related to mental health

-11.7

[-14.8; -8.7]

p < .0001

 

Side effects related to body modification

-3.9

[-6.3; -1.4]

p < 0.0020

GH R2 = 0.18

Intercept

63.8

[62.1; 65.5]

p < .0001

 

Hospitalization in the last 4 weeks

-6.1

[-10.2; -2]

p < 0.0038

 

Critical illness in the last 4 weeks

-7.1

[-13.5; -0.7]

p < 0.0305

 

Diabetes

-5.4

[-9; -1.7]

p < 0.0038

 

Side effects related to general health

-11.6

[-15.1; -8.1]

p < .0001

 

Side effects related to mental health

-7.7

[-11.1; -4.2]

p < .0001

 

Side effects related to body modification

-5.6

[-8.4; -2.9]

p < .0001

 

Non-compliant

-6.3

[-9.2; -3.4]

p < .0001

PCS (R2 = 0.28)

Intercept

52.7

[50.9; 54.5]

p < .0001

 

Female

-1.7

[-3; -0.4]

p < 0.0084

 

Age ≥ 75 years

-7.7

[-11; -4.3]

p < .0001

 

Low educational (primary or less)

-3.3

[-4.9; -1.7]

p < .0001

 

Unemployment

-2.5

[-3.8; -1.1]

p < 0.0003

 

Critical illness in the last 4 weeks

-5.7

[-8.8; -2.6]

p < 0.0003

 

Infectious disease in the last 4 weeks

-3.2

[-5.1; -1.3]

p < 0.0012

 

Side effects related to general health

-9.2

[-10.8; -7.5]

p < .0001

MCS (R2 = 0.22)

Intercept

52.1

[50.3; 54]

p < .0001

 

Female

-1.7

[-3; -0.4]

p < 0.0113

 

Family status (living alone)

-2.2

[-3.7; -0.7]

p < 0.0039

 

Hospitalization in the last 4 weeks

-5.7

[-7.8; -3.6]

p < .0001

 

Side effects related to body modification

-2.5

[-3.9; -1.1]

p < 0.0005

 

Side effects related to mental health

-9.3

[-11; -7.7]

p < .0001